| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/30/2010 | WO2010109706A1 Therapeutic agent for cancer having reduced sensitivity to molecular targeted drug, and pharmaceutical composition for enhancing sensitivity to molecular targeted drug |
| 09/30/2010 | WO2010109325A2 Combinations including pneumococcal serotype 14 saccharide |
| 09/30/2010 | WO2010109324A1 Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| 09/30/2010 | WO2010109323A1 Adjuvanting meningococcal factor h binding protein |
| 09/30/2010 | WO2010109284A1 Antimicrobial cationic lipo-beta-peptides |
| 09/30/2010 | WO2010109042A1 Composition for the prevention or treatment of diabetes mellitus |
| 09/30/2010 | WO2010109010A1 Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
| 09/30/2010 | WO2010108977A1 Vaccine for protection against streptococcus suis bacteria of various serotypes |
| 09/30/2010 | WO2010108824A1 L-plastin antibodies and their use |
| 09/30/2010 | WO2010108682A1 Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof |
| 09/30/2010 | WO2010108215A1 Compounds and methods for modulating an immune response |
| 09/30/2010 | WO2010076400A8 Use of an anti-cd20 antibody for treating primary intraocular lymphoma |
| 09/30/2010 | WO2010065950A3 Albumin binding peptide-mediated disease targeting |
| 09/30/2010 | WO2010062859A3 Recombinantly expressed plasmodium celtos antigen and methods of use thereof |
| 09/30/2010 | WO2010045388A3 Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
| 09/30/2010 | WO2010030813A3 Methods for inhibiting ocular angiogenesis |
| 09/30/2010 | WO2009156960A9 Novel adjuvant compositions |
| 09/30/2010 | WO2009047610A8 Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
| 09/30/2010 | US20100249372 Botulinum neurotoxin a receptor and the use thereof |
| 09/30/2010 | US20100249034 Gfralpha3 and its uses |
| 09/30/2010 | US20100248334 Biological active coating components, coatings, and coated surfaces |
| 09/30/2010 | US20100248240 Gene and protein relating to hepatocellular carcinoma and methods of use thereof |
| 09/30/2010 | US20100247663 Microspheres |
| 09/30/2010 | US20100247662 Biologic Modulations with Nanoparticles |
| 09/30/2010 | US20100247661 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces |
| 09/30/2010 | US20100247657 Telomerase reverse transcriptase variant |
| 09/30/2010 | US20100247650 Treatment for pre-eclampsia in pregnant women using targeted apheresis |
| 09/30/2010 | US20100247627 Foxn1 and pigmentation |
| 09/30/2010 | US20100247625 Orally Bioavailable Lipid-Based Constructs |
| 09/30/2010 | US20100247624 Vaccine compositions and methods containing an immunogen derived from equine arteritis virus |
| 09/30/2010 | US20100247623 Cancer Stem Cell Vaccine |
| 09/30/2010 | US20100247622 Treatment regime for proliferative disorders |
| 09/30/2010 | US20100247621 Codon modified immunogenic compositions and methods of use |
| 09/30/2010 | US20100247618 Novel synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV |
| 09/30/2010 | US20100247580 Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy |
| 09/30/2010 | US20100247579 Therapeutic agent for cancer |
| 09/30/2010 | US20100247578 Carrier system for biological agents containing organosilicon compounds and uses thereof |
| 09/30/2010 | US20100247577 Tr1 cells, mesenchymal stem cells and uses thereof |
| 09/30/2010 | US20100247576 Nucleotide and amino acid sequences encoding an exported protein 1 derived from plasmodium vivax and uses thereof |
| 09/30/2010 | US20100247575 Agents for promoting iga production |
| 09/30/2010 | US20100247574 CHIMERIC NEWCASTLE DISEASE VIRUS VLPs |
| 09/30/2010 | US20100247573 Stabilization of Vaccines by Lyophilization |
| 09/30/2010 | US20100247572 Viruses encoding mutant membrane protein |
| 09/30/2010 | US20100247571 Methods and compositions for immunization against virus |
| 09/30/2010 | US20100247570 High Mannose Glycoprotein Epitopes |
| 09/30/2010 | US20100247569 Influenza A Virus Vaccines and Inhibitors |
| 09/30/2010 | US20100247568 Novel adjuvant |
| 09/30/2010 | US20100247567 Composition and method for controlling intestinal pathogenic organisms |
| 09/30/2010 | US20100247566 Cholera vaccines |
| 09/30/2010 | US20100247565 Chimeric sindbis-eastern equine encephalitis virus and uses thereof |
| 09/30/2010 | US20100247562 Complexes Derived from Heterohybrid Cells and Uses Thereof |
| 09/30/2010 | US20100247561 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 09/30/2010 | US20100247560 Mutant botulinum neurotoxin serotype a polypeptide and uses thereof |
| 09/30/2010 | US20100247559 West nile virus vaccine, and method for production thereof |
| 09/30/2010 | US20100247558 PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE |
| 09/30/2010 | US20100247557 Immunostimulant Composition Comprising At Least One Toll-Like Receptor 7 Or Toll-Like Receptor 8 Agonist And A Toll-Like Receptor 4 Agonist |
| 09/30/2010 | US20100247556 Method for activation of helper t cell and composition for use in the method |
| 09/30/2010 | US20100247555 Reversibly inhibited antibodies for immune cell stimulation |
| 09/30/2010 | US20100247554 Use of tam receptor inhibitors as antimicrobials |
| 09/30/2010 | US20100247553 Goodpasture Antigen Binding Protein |
| 09/30/2010 | US20100247552 Pak modulators |
| 09/30/2010 | US20100247551 Use of Lipocalin 2 in the Regulation of Insulin Sensitivity |
| 09/30/2010 | US20100247550 Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds |
| 09/30/2010 | US20100247549 Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| 09/30/2010 | US20100247548 Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders |
| 09/30/2010 | US20100247547 Modulation of the th-17 cell mediated immune responses |
| 09/30/2010 | US20100247546 Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| 09/30/2010 | US20100247545 Antibodies to m-csf |
| 09/30/2010 | US20100247544 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms |
| 09/30/2010 | US20100247543 Treatment and prevention of neurodegenerative diseases |
| 09/30/2010 | US20100247542 Truncated variant of the mammalian target for rapamycin (mtor) protein |
| 09/30/2010 | US20100247541 novel antigen associated with the neovasculature of tumour metastases |
| 09/30/2010 | US20100247540 Methods and Compositions For Modulating Angiogenesis |
| 09/30/2010 | US20100247539 Antibodies that Inhibit Transport Activity of Peptide Transporters |
| 09/30/2010 | US20100247538 IL-18 and Protein Kinase R Inhibition for the Treatment of COPD |
| 09/30/2010 | US20100247537 Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity |
| 09/30/2010 | US20100247536 Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications |
| 09/30/2010 | US20100247535 Chemically Programmable Immunity |
| 09/30/2010 | US20100247534 Fused heterocyclic compounds as inhibitors of potassium channel function |
| 09/30/2010 | US20100247533 TREATMENT WITH A HUMANIZED ANTI-EGFR IgG1 ANTIBODY AND IRINOTECAN |
| 09/30/2010 | US20100247532 Humanized anti-venezuelan equine encephalitis virus recombinant antibodies |
| 09/30/2010 | US20100247531 Anti-fgfr3 antibodies and methods using same |
| 09/30/2010 | US20100247530 Compositions and methods for preventing and treating presbycusis |
| 09/30/2010 | US20100247529 Cooperative and dynamic assembly of affinity complexes |
| 09/30/2010 | US20100247528 Arrays, kits and cancer characterization methods |
| 09/30/2010 | US20100247527 Composition and method for treatment of autoimmune disease |
| 09/30/2010 | US20100247526 Anti-NKG2A Antibodies and Uses Thereof |
| 09/30/2010 | US20100247525 Compositions and methods for treating anthrax lethality |
| 09/30/2010 | US20100247524 Methods for treating Chronic Obstructive Pulmonary Disease |
| 09/30/2010 | US20100247523 Subtypes of humanized antibody against interleuken-6 receptor |
| 09/30/2010 | US20100247522 Linked purine pterin hppk inhibitors useful as antibacterial agents |
| 09/30/2010 | US20100247521 Therapeutic and Diagnostic Methods Using TIM-3 |
| 09/30/2010 | US20100247520 Mutated netrin 4, fragments thereof and uses thereof as drugs |
| 09/30/2010 | US20100247519 Heterocyclic aspartyl protease inhibitors |
| 09/30/2010 | US20100247518 Modified proteins, designer toxins, and methods of making thereof |
| 09/30/2010 | US20100247517 Use of mnk inhibitors for the treatment of alzheimer's disease |
| 09/30/2010 | US20100247516 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| 09/30/2010 | US20100247515 Polypeptides, antibody variable domains and antagonists |
| 09/30/2010 | US20100247514 Gamma secretase modulators |
| 09/30/2010 | US20100247502 Tumor/b-cell hybrid cells and uses thereof |